New 'Living Drug' trial targets tough blood cancers
NCT ID NCT07345728
Summary
This study is testing the safety and effectiveness of a new type of CAR-T cell therapy for adults with B-cell blood cancers that have come back or stopped responding to other treatments. Doctors will collect and modify a patient's own immune cells to target a protein called BAFFR on cancer cells. The goal is to see if this one-time treatment can help control the disease and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, 448000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.